0001659819-17-000001.txt : 20170420 0001659819-17-000001.hdr.sgml : 20170420 20170420111135 ACCESSION NUMBER: 0001659819-17-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170420 DATE AS OF CHANGE: 20170420 EFFECTIVENESS DATE: 20170420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Velicept Therapeutics, Inc. CENTRAL INDEX KEY: 0001659819 IRS NUMBER: 473400632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-252193 FILM NUMBER: 17771917 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-318-2988 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 400 CITY: MALVERN STATE: PA ZIP: 19355 D/A 1 primary_doc.xml X0707 D/A LIVE 0001659819 Velicept Therapeutics, Inc. 101 LINDENWOOD DRIVE SUITE 125 MALVERN PA PENNSYLVANIA 19355 484-318-2988 DELAWARE None None Corporation true 2015 James Walker 101 Lindenwood Drive Suite 125 Malvern PA PENNSYLVANIA 19355 Executive Officer Director Douglas Gessl 101 Lindenwood Drive Suite 125 Malvern PA PENNSYLVANIA 19355 Executive Officer Stephen Tullman 101 Lindenwood Drive Suite 125 Malvern PA PENNSYLVANIA 19355 Director Scott Morenstein 500 Park Avenue New York NY NEW YORK 10022 Director David Hirsch One Fawcett Place Greenwich CT CONNECTICUT 06830 Director James Bennethum 860 Porcupine Path Gaylord MI MICHIGAN 49735 Director Pharmaceuticals Decline to Disclose 06b true 0001659819-15-000001 2015-11-23 true true false 4485 MTS Securities, LLC 104059 None None 623 Fifth Avenue 14th Floor New York NY NEW YORK 10022 All States false William Blair & Company 1252 None None 125 High Street Oliver Tower, Suite 1901 Boston MA MASSACHUSETTS 02110 All States false 26300003 18410010 7889993 true 2 25 1250000 true 0 $920,500 has been paid or is due to MTS Securities and $250,000 has been paid to William Blair in connection with the sold shares; additional payment of $79,500 to MTS Securities is due upon the sale of the remaining $7,889,993.52 of securities. 750000 true false Velicept Therapeutics, Inc. James Walker James Walker President and CEO 2017-04-20